Friday, 16 October 2026
Provider directory transfer, Rural healthcare spending gap widens, Unapproved medicine import fines
- 01
National provider directory to transfer to ADHA in November
The Healthcare Provider Directory is expected to transition to the Australian Digital Health Agency (ADHA) in November 2026 following a Federal Government decision. The ADHA will operate the directory under the Healthcare Identifiers Act 2010 through the Health Connect Australia Provider Directory, which will include information held in the Healthcare Identifiers Service. The directory is intended to help authorised providers and organisations find and connect with GPs, support referrals and care coordination, and securely exchange information as patients move between care settings. GPs are advised to review and update their details through Provider Connect Australia, AHPRA or the Healthcare Identifiers Service.
via RACGP newsGP
- 02
Rural healthcare spending gap widens to $9.23 billion
The annual healthcare spending gap between rural and urban Australia widened to $9.23 billion in 2024–25, according to National Rural Health Alliance analysis conducted by the Nous Group. The estimated shortfall was $1218 per rural resident, representing a $138 real-term increase in inequity since last year. Differences in public hospital, private health, aged care and MBS funding accounted for most of the deficit, while the widening was mainly attributed to declining private hospital expenditure and deteriorating rural private hospital viability. Age-standardised MBS spending fell from $1535 per person in MMM 1 areas to $811 in MMM 7, and telehealth spending also decreased with remoteness. The report called for governments to define a reasonable level of accessible care in remote areas and develop a new national rural and remote health strategy.
via RACGP newsGP
- 03
TGA fines importers over unapproved prescription medicines and injectables
The TGA issued 12 infringement notices worth a combined $126,720 to two companies and five individuals for alleged breaches involving imported or advertised medicines. Individual penalties covered the importation of Mounjaro (tirzepatide) pens, prescription-only erectile-dysfunction medicines and cosmetic injectable products in pre-filled hyaluronic acid syringes. The largest penalty was $59,400 against the Australian Centre for Functional Medicine over unapproved melatonin products, while separate notices concerned advertising of lovastatin, baricitinib and ketamine. The TGA said the products were not included on the Australian Register of Therapeutic Goods and lacked the approval, authority or exemption required for importation or advertising. Under the Personal Importation Scheme, prescription-only medicines require valid written authority such as an Australian prescription, and imports are limited to no more than a three-month supply.
- 04
CGM lowered HbA1c in non-insulin-treated type 2 diabetes
Continuous glucose monitoring produced a larger HbA1c reduction than routine care after 26 weeks among people with type 2 diabetes who did not take insulin. The Dexcom-funded US trial enrolled 440 people across 22 primary care practices and tested the company’s G7 device. Mean HbA1c fell from 8.8% to 7.2% in the CGM group, compared with 8.7% to 8.0% in the routine-care group, while CGM users spent five additional hours per day in the target glucose range. Dexcom said the benefits were consistent across demographic, clinical and socioeconomic groups. The results were published in the New England Journal of Medicine as Dexcom awaited a Centers for Medicare and Medicaid Services decision on expanding Medicare coverage to people with diabetes who do not use insulin.
via MedTech Dive
- 05
FDA plans more flexible rare disease drug review framework
The US Food and Drug Administration plans to develop a more flexible, condition-specific framework for regulating rare disease therapies rather than applying a one-size-fits-all approach. Its Rare Disease Framework Initiative will review existing policies, gather input from patients and experts, and examine development and regulation from preclinical engagement through post-marketing requirements. The agency did not set a timeline for initial recommendations, but will seek feedback at a meeting on 28 October. The initiative could affect evidence standards and approval pathways for medicines targeting small patient populations, amid FDA figures showing that about 5% of recognised rare conditions had an approved treatment as of last year.
via BioPharma Dive · also covered by Healthcare Dive
- 06
CHMP backs daraxonrasib for previously treated metastatic pancreatic cancer
The CHMP has recommended marketing authorisation for Rasonque (daraxonrasib) as monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The RAS GTPase inhibitor was associated with longer median overall survival and progression-free survival than standard chemotherapy. The most common adverse effects were rash, diarrhoea, stomatitis, nausea and vomiting. Rasonque will be available as 100 mg and 150 mg film-coated tablets and should be initiated by physicians experienced in using anticancer medicines. The European Commission will decide whether to grant marketing authorisation, while the EMA will review whether the medicine’s orphan designation can be maintained.
via European Medicines Agency Human Medicines · also covered by European Medicines Agency News
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.